Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

17.28 +0.18 (+1.05%)
Official Closing Price Updated: 7:00 PM EDT, Jul 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,440,253
Open 17.13
Bid (Size) 17.01 (31)
Ask (Size) 17.28 (2)
Prev. Close 17.10
Today's Range 17.07 - 17.39
52wk Range 7.950 - 17.69
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire

Performance

YTD
+61.95%
+61.95%
1 Month
-0.35%
-0.35%
3 Month
+24.59%
+24.59%
6 Month
+51.58%
+51.58%
1 Year
+114.13%
+114.13%

More News

Read More
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Dr. Reddy's Labs Stock Sees Improved Technical Strength
Via Investor's Business Daily
Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Via Benzinga
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
Via Benzinga
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Engages In Settlement Talks Over Medicare Kickback Allegations
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know
Via Benzinga
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
What is a Bull Flag Pattern? Explanation and Examples
Via MarketBeat
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 Generic Drug Makers With Growing Runways
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
Via Benzinga
Topics Cannabis
Exposures Cannabis
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
From Teva Pharmaceutical Industries Limited
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.